Please login to the form below

CD3

This page shows the latest CD3 news and features for those working in and with pharma, biotech and healthcare.

Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

Sanofi and Regeneron are also working on bispecific antibody immunotherapies, including two lead candidate targeting BCMA/CD3 and MUC/CD3, respectively.

Latest news

Regeneron reveals first data for bispecific antibody in multiple myeloma

The antibody targets BCMA, a protein that is typically over-expressed on multiple myeloma cells, by binding to it and the CD3 receptor on T-cells, bringing them together and activating ... CD3 targeting bispecific antibody.
Provention Bio wins PRIME designation for type 1 diabetes prevention drug

Teplizumab works by binding to the pro-inflammatory T cell co-receptor CD3, which in turn prevents them from activating the T cells that attack and kill the pancreas’ beta cells.
Tiziana joins type 1 diabetes prevention field

Teplizumab is a mouse derived anti-CD3 mAb, and is administered intravenously. ... Now Tiziana is looking to rival Provention with the development of its own anti-CD3 mAB foralumab, which it says is the only entirely human anti-CD3 mAb.
Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy

Roche is also looking at combining Polivy with its CD20/CD3 bispecific antibody mosunetuzumab in DLBCL and follicular lymphoma, and moving the ADC into earlier lines of therapy.
Type 1 diabetes prevention promise sends Provention Bio soaring

Teplizumab works by binding to the pro-inflammatory T cell co-receptor CD3, which in turn prevents them from activating the T cells that attack and kill the pancreas’ beta cells.

More from news
Approximately 2 fully matching, plus 23 partially matching documents found.

Latest Intelligence

Taking a lean and careful approach

Its fully human engineered CD3 antibody Foralumab has reached phase II with potential for a wide range of autoimmune and inflammatory diseases such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis,
Deal Watch June 2016

Both antibodies have a cytotoxic T-cell binding domain (CD3), which activates T-cells at the site of the tumour for killing of malignant cells, and a specific tumour antigen binding
Pharma deals during December 2014

platform. The antibody targets both CD19 and CD3 and is being developed for the treatment of B-cell malignancies.
Deal Watch table for August 2014

187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).
Pharma deals during February 2014

CD123 and CD3.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences

Shailubhai takes the helm as Tiziana focuses on developing an orally administered, anti-CD3 mAb (foalumab) drug candidate to manage non-alcoholic steatohepatitis (NASH) - a liver disease that has no treatment

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director – Cheshire based Medical Communications Agency...: D.O.E

Senior Medical Writer – Leading Medical Communications Agency – ...: Highly Competitive Remuneration Package

Senior Medical Writer– Medical Education – Oxford - London: Excellent Remuneration Package

Experienced / Senior Medical Writer - MedComms - Cardiff - Wales: Excellent Salary and Benefits on offer

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Senior Medical Writer: Salary TBC

Scientific Director - Medical Communications Agency - New York: Excellent Remuneration Package

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Account Director, Medical Education: Salary TBC

Graduate / Entry Level Opportunities – Medical Communications – ...: Highly Competitive Remuneration Package

Scientific Director - Medical Education - Cheshire & London ...: Excellent Remuneration Package

Senior / Principal Medical Writer – Medical Education - UK &...: Excellent Salary and Benefits on offer

Subscribe to our email news alerts

PMHub

Add my company

Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

The 2019 CPhI Pharma Index Report: Examining this year’s industry performance...
Five key trends in precision and personalised healthcare: Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications: Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...